Veru Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VERU research report →
Companywww.verupharma.com
Veru Inc. , an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.
- CEO
- Mitchell S. Steiner
- IPO
- 1999
- Employees
- 210
- HQ
- Miami, FL, US
Price Chart
Valuation
- Market Cap
- $34.83M
- P/E
- -3.37
- P/S
- 0.00
- P/B
- 1.35
- EV/EBITDA
- -0.36
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -52.86%
- ROIC
- -49.46%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-22,726,279 · 39.88%
- EPS
- $-1.07 · 61.79%
- Op Income
- $-24,750,642
- FCF YoY
- -37.56%
Performance & Tape
- 52W High
- $7.40
- 52W Low
- $2.05
- 50D MA
- $2.31
- 200D MA
- $2.82
- Beta
- -1.17
- Avg Volume
- 56.00K
Get TickerSpark's AI analysis on VERU
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 4, 26 | STEINER MITCHELL SHUSTER | other | 604,000 |
| May 4, 26 | Greco Michele | other | 164,000 |
| May 4, 26 | Katzovitz Loren Mark | other | 102,000 |
| May 4, 26 | Hyun Grace | other | 97,000 |
| May 4, 26 | Rankowitz Michael L | other | 100,000 |
| May 4, 26 | Lu Lucy | other | 104,000 |
| May 4, 26 | BARNETTE K GARY | other | 160,000 |
| May 4, 26 | FISCH HARRY | other | 160,000 |
| Dec 5, 25 | BARNETTE K GARY | other | 27,000 |
| Dec 5, 25 | Rankowitz Michael L | other | 3,000 |
Our VERU Coverage
We haven't published any research on VERU yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VERU Report →